RxDoctor Payments DataLook up a doctor →

Scott Dorroh, MD

Hematology & Oncology · Jonesboro, ARNPI 1124231816

Payments from drug & device makers

$200,455in general payments, 2019–2025

Across 364 payments — averaging $550.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$166K
  • Novartis$27K
  • AstraZeneca$1K
  • Pfizer$492
  • Merck$464
  • Sumitomo Pharma America, Inc.$300
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$5,90091%
  • Education$5749%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,455 in reported general payments places this provider in the 80th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$118,532
Medicare patients
522
Services billed
1,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide101$1,445,112
CabometyxCabozantinib S-Malate31$766,316
ScemblixAsciminib Hydrochloride19$296,748
RevlimidLenalidomide15$284,138
BrukinsaZanubrutinib16$242,293
BosulifBosutinib14$226,911
CalquenceAcalabrutinib Maleate12$184,783
ErleadaApalutamide11$167,317
KisqaliRibociclib Succinate12$134,429
Abiraterone Acetate20$132,748
Gefitinib18$57,860
EliquisApixaban75$48,879
Imatinib Mesylate35$29,460
XareltoRivaroxaban18$13,882
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen150$5,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$107$1,445,112101 claims
Exelixis Inc.Cabometyx$289$766,31631 claims
NovartisScemblix, Kisqali$27,020$431,17731 claims
Bristol Myers SquibbRevlimid$40$284,13815 claims
PfizerBosulif, Eliquis$492$275,79189 claims
Beigene USA, Inc.Brukinsa$69$242,29316 claims
AstraZenecaCalquence, Symbicort$1,491$187,68224 claims
Johnson & JohnsonErleada, Xarelto$165$181,19929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →